News

Community Care Releases 'Best Practices In The Use Of Buprenorphine'

PITTSBURGH (Dec. 14, 2011) - "Best Practices in the Use of Buprenorphine," - an initiative that identifies guidelines for providers and payers to enhance the use of buprenorphine and address quality concerns related to its use - has been released by Community Care Behavioral Health Organization. Developed by the Institute for Research, Education, and Training in Addictions (IRETA) with support and assistance from Community Care, "Best Practices in the Use of Buprenorphine" is available on the Community Care website at http://www.ccbh.com/buprenorphine.

In addition, Community Care has completed an analysis of patterns of medication-assisted treatment of opioid dependence. The analysis was led by Bradley Stein, MD, PhD. An article describing this analysis will appear in a forthcoming issue of "Drug and Alcohol Dependence," one of the leading substance-abuse, peer-reviewed journals.

Buprenorphine is a narcotic analgesic used to provide medication-assisted treatment for opiate addiction by community-based providers who work outside of methadone programs. Buprenorphine is marketed under the brand name Subutex® and buprenophine/naloxone is marketed under the brand name Suboxone®. Community Care is committed to continued work with its members, providers, and other stakeholders to improve the value of this novel treatment for opiate addiction.

< Back to News